PIK3CA and breast carcinoma: C1 was mainly characterized by enrichment of PIK3CA (25%) and RB1 mutations (21%), PIK3CA mutation test helps to distinguish between tumors (indeed supported by PI3K activation) and cancers characterized by participation in other signaling pathways, while PIK3CA inhibitors show satisfactory activity in breast cancer [48].